Guardant Health Makes Big Impact at Precision Medicine World Conference (PMWC 2024) in Silicon Valley

Guardant Health was on prominent display at the recent Precision Medicine World Conference (PMWC 2024) (January 24-26) in Silicon Valley. The company’s co-founders and co-CEOs, Helmy Eltoukhy, PhD, and AmirAli Talasaz, PhD, were each presented with a PMWC Luminary Award for their work transforming the precision oncology field through the development of the advanced non-invasive liquid biopsy. Both received their PhDs in electrical engineering from Stanford and believe this training allows them to bring an engineering “problem-solving” approach to biology. At the PMWC, Dr. Eltoukhy moderated a panel discussion on “Status Quo of Clinical Liquid Biopsy” and Dr. Talasaz participated in a panel discussion on “Liquid Biopsy for Health Monitoring and Disease Prevention.” Guardant Health, a global organization headquartered in Palo Alto, California, is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.

Login Or Register To Read Full Story